Allergy to Omalizumab: Lessons from a Reaction to the Coronavirus 2019 Vaccine

Omalizumab can cause hypersensitivity reactions. We herein report the first case of an 18-year-old woman with refractory cough-predominant asthma that correlated with allergic reactions caused by omalizumab and the coronavirus disease 2019 (COVID-19) vaccine. The patient developed angioedema after t...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Takeshi, Sakurai, Yumiko, Fujiki, Takahiro, Kusakabe, Yusuke, Nakayama, Emi, Tanaka, Ayaka, Yamamoto, Naoki, Aihara, Kensaku, Yamaoka, Shinpachi, Mishima, Michiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183271/
https://www.ncbi.nlm.nih.gov/pubmed/36725035
http://dx.doi.org/10.2169/internalmedicine.1169-22
Descripción
Sumario:Omalizumab can cause hypersensitivity reactions. We herein report the first case of an 18-year-old woman with refractory cough-predominant asthma that correlated with allergic reactions caused by omalizumab and the coronavirus disease 2019 (COVID-19) vaccine. The patient developed angioedema after taking omalizumab. She had previously experienced intense coughing immediately after receiving a COVID-19 vaccine. A skin prick test was positive for polysorbate 20, which was probably the cause of the allergic reactions to omalizumab and the COVID-19 vaccine. Clinicians should check for an allergic reaction, irrespective of its intensity, triggered by polysorbate and be careful when prescribing biologics to patients in order to avoid allergic reactions.

Ejemplares similares